Related references
Note: Only part of the references are listed.AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis
Joseph D. Feuerstein et al.
GASTROENTEROLOGY (2020)
Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease
Youn I. Choi et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2019)
Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts
Ryan C. Ungaro et al.
GUT (2019)
ACG Clinical Guideline: Ulcerative Colitis in Adults
David T. Rubin et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)
No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials
Siddharth Singh et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management (vol 11, pg 769, 2017)
Marcus Harbord et al.
JOURNAL OF CROHNS & COLITIS (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders
Fernando Magro et al.
JOURNAL OF CROHNS & COLITIS (2017)
Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease
Donal Tighe et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease
S. Bonovas et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus
Brian Bressler et al.
GASTROENTEROLOGY (2015)
Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis
R. W. Stidham et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Biological Agents for Moderately to Severely Active Ulcerative Colitis A Systematic Review and Network Meta-analysis
Silvio Danese et al.
ANNALS OF INTERNAL MEDICINE (2014)
5-Aminosalicylic Acid Is Not Protective Against Colorectal Cancer in Inflammatory Bowel Disease: A Meta-Analysis of Non-Referral Populations
Geoffrey C. Nguyen et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
The Role of Chemoprevention of Colorectal Cancer with 5-Aminosalicylates in Ulcerative Colitis
Hans Herfarth
DIGESTIVE DISEASES (2012)
Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Cost-Effectiveness of 5-Aminosalicylic Acid Therapy for Maintenance of Remission in Ulcerative Colitis
Eugene F. Yen et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines
RAJ Ransford et al.
GUT (2002)
Share Paper
